What question did this study set out to answer?

To determine whether initial tumor response assessed by modified RECIST (mRECIST) criteria correlates with one-year survival and to identify predictors of tumor response in patients undergoing drug-eluting bead chemoembolization.

January 1, 2015Journal of Cancer TherapyOpen Access

Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug-Eluting Beads

View Full Paper

Ask AI

Bookmark

Authors

NQNatália Sousa Freitas QueirozSolarea Bio (United States)LKLuciana KikuchiBayer (Germany)RBRégis Otaviano França BezerraHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Discussion

Member takes

Implication

Cohort study reveals complete tumor response by mRECIST predicts improved one-year survival in hepatocellular carcinoma treated with drug-eluting bead chemoembolization, indicating early imaging...

Key Points

To determine whether initial tumor response assessed by modified RECIST (mRECIST) criteria correlates with one-year survival and to identify predictors of tumor response in patients undergoing drug-eluting bead chemoembolization.
Monitored 52 patients with hepatocellular carcinoma undergoing transarterial chemoembolization with drug-eluting beads (TACE-DEB) loaded with 75 mg doxorubicin over a 6-month period.
Evaluated initial radiological tumor response at 1 month post-procedure according to mRECIST guidelines.
At 1 month, mRECIST response rates were 23% (12/52) complete response, 37% (19/52) partial response, 8% (4/52) stable disease, and 32% (17/52) progressive disease.
Overall 1-year survival was 74% (95% in BCLC stage A vs. 56% in BCLC stage B), with complete response achieving higher 1-year survival than non-complete response (100% vs. 64%).
Baseline tumor diameter ≤58 mm and BCLC stage A independently associated with achieving a complete response.

Cite This Study

Queiroz et al. (2015) studied this question.

synapsesocial.com/papers/6ab378ef329566e6f1bab04d https://doi.org/10.4236/jct.2015.613121

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals complete tumor response by mRECIST predicts improved one-year survival in hepatocellular carcinoma treated with drug-eluting bead chemoembolization, indicating early imaging...

Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug-Eluting Beads

Discussion

Member takes

Implication

Key Points

Cite This Study

Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug-Eluting Beads

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider